enGene Therapeutics reported total assets of $288.32M and total liabilities of $58.03M for the quarter ended Jul 2026, up 17.4% year over year. This balance sheet covers 16 quarters of results from Oct 2022 through Jul 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Oct2022 | Jan2023 | Apr2023 | Jul2023 | Oct2023 | Jan2024 | Apr2024 | Jul2024 | Oct2024 | Jan2025 | Apr2025 | Jul2025 | Oct2025 | Jan2026 | Apr2026 | Jul2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accumulated Depreciation | 1.55M | 1.73M | 1.81M | 1.89M | 1.53M | 1.61M | 1.71M | 1.82M | 1.93M | 2.10M | 2.29M | 2.46M | 2.63M | |||
| Assets | ||||||||||||||||
| Current Assets | ||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 20.43M | 81.52M | 85.65M | 264.81M | 257.68M | 173.00M | 62.35M | 57.55M | 32.62M | 50.15M | 36.61M | 29.83M | 41.02M | |||
| Prepaid Assets | 0.74M | 1.50M | 2.72M | 3.51M | 4.70M | 8.63M | 8.00M | 9.98M | 8.62M | 6.65M | 12.00M | 10.64M | 10.53M | |||
| Current Assets | 22.58M | 85.44M | 89.58M | 269.61M | 262.69M | 247.36M | 222.32M | 227.97M | 211.31M | 201.39M | 289.22M | 270.00M | 277.90M | |||
| Non-Current Assets | ||||||||||||||||
| Property, Plant & Equipment (Net) | 0.39M | 0.59M | 0.99M | 1.11M | 1.01M | 1.17M | 1.37M | 1.55M | 1.88M | 2.48M | 2.44M | 2.33M | 2.16M | |||
| Long-Term Investments | 59.53M | 58.98M | 34.11M | 23.01M | 8.52M | 36.60M | 26.71M | |||||||||
| Other Non-Current Assets | 0.94M | 0.93M | 0.97M | 0.97M | 1.38M | 1.37M | 1.58M | 1.38M | 1.38M | 1.36M | 1.39M | 1.38M | 1.39M | |||
| Non-Current Assets | 1.33M | 1.52M | 3.84M | 3.92M | 4.18M | 63.81M | 63.61M | 38.68M | 34.24M | 20.08M | 47.90M | 37.52M | 10.42M | |||
| Assets | 23.91M | 86.96M | 93.42M | 273.53M | 266.88M | 311.17M | 285.93M | 266.65M | 245.55M | 221.47M | 337.11M | 307.52M | 288.32M | |||
| Liabilities | ||||||||||||||||
| Current Liabilities | ||||||||||||||||
| Accounts Payables | 0.72M | 1.16M | 1.27M | 0.21M | 2.86M | 1.41M | 2.60M | 1.57M | 2.38M | 6.69M | 2.44M | 1.79M | 2.54M | |||
| Notes Payables | 1.26M | 39.98M | 0.56M | 1.34M | 0.70M | 1.69M | 3.57M | 5.41M | 8.00M | 0.19M | 0.19M | 0.20M | ||||
| Payables | 1.99M | 39.98M | 1.72M | 1.27M | 0.21M | 4.20M | 2.11M | 4.29M | 5.14M | 7.80M | 14.69M | 2.62M | 1.99M | 2.74M | ||
| Accumulated Expenses | 3.12M | 3.54M | 5.24M | 5.67M | 8.83M | 12.13M | 8.24M | 12.43M | 11.12M | 15.28M | 19.67M | 17.21M | 22.22M | |||
| Other Accumulated Expenses | 0.11M | 0.06M | 0.27M | 0.40M | 0.23M | 0.56M | 0.51M | 0.61M | 0.58M | 0.23M | 0.95M | 0.67M | ||||
| Current Leases | 0.39M | 0.42M | 0.42M | 0.42M | 0.42M | 0.43M | 1.53M | 2.01M | 2.32M | 2.29M | 2.25M | |||||
| Current Taxes | 0.02M | 0.04M | 0.01M | 0.03M | 0.09M | 0.33M | 0.57M | 0.02M | ||||||||
| Total Current Liabilities | 5.10M | 5.26M | 6.91M | 6.30M | 13.46M | 14.66M | 12.96M | 18.00M | 20.44M | 31.98M | 24.61M | 21.48M | 27.21M | |||
| Non-Current Liabilities | ||||||||||||||||
| Non-Current Debt | 9.65M | 9.22M | 22.53M | 22.73M | 21.61M | 22.47M | 21.70M | 20.02M | 17.71M | 15.32M | 24.74M | 24.91M | 25.16M | |||
| Convertible Debt | 17.41M | |||||||||||||||
| Preferred Stock Liabilities | 49.66M | 49.66M | 49.66M | |||||||||||||
| Operating Leases | 1.60M | 1.53M | 1.48M | 1.43M | 1.33M | 1.34M | 6.73M | 6.46M | 6.22M | 5.96M | 5.67M | |||||
| Other Non-Current Liabilities | 11.46M | |||||||||||||||
| Total Non-Current Liabilities | 35.95M | 14.47M | 31.04M | 30.56M | 36.55M | |||||||||||
| Total Liabilities | 47.41M | 84.01M | 89.24M | 93.92M | 14.47M | 31.04M | 30.56M | 36.55M | 38.56M | 35.98M | 39.36M | 44.88M | 53.76M | 55.57M | 52.36M | 58.03M |
| Shareholder's Equity | ||||||||||||||||
| Total Debt | 10.91M | 39.98M | 9.78M | 22.53M | 22.73M | 22.95M | 23.17M | 23.39M | 23.59M | 23.12M | 23.33M | 24.92M | 25.10M | 25.35M | ||
| Common Equity | -76.61M | -84.01M | -89.24M | -93.92M | 72.49M | 62.38M | 242.97M | 230.33M | 272.61M | 249.95M | 227.29M | 200.67M | 167.71M | 281.55M | 255.17M | 230.29M |
| Liabilities and Shareholders Equity | 23.91M | 86.96M | 93.42M | 273.53M | 266.88M | 311.17M | 285.93M | 266.65M | 245.55M | 221.47M | 337.11M | 307.52M | 288.32M | |||
| Retained Earnings | -99.67M | -199.59M | -210.30M | -225.30M | -239.43M | -254.73M | -279.35M | -305.20M | -334.20M | -372.03M | -401.80M | -432.01M | -464.51M | |||
| Treasury Shares | 5.56M | 5.56M | 5.56M | 5.56M |